Last updated on October 2018

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)


Brief description of study

The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.

Clinical Study Identifier: NCT02318277

Contact Investigators or Research Sites near you

Start Over

Incyte Corporation Call Center (US)

San Francisco, CA United States

Incyte Corporation Call Center (US)

Denver, CO United States

Incyte Corporation Call Center (US)

Miami, FL United States

Incyte Corporation Call Center (US)

Port Saint Lucie, FL United States

Incyte Corporation Call Center (US)

Sarasota, FL United States

Incyte Corporation Call Center (US)

Tampa, FL United States

Incyte Corporation Call Center (US)

Chicago, IL United States

Incyte Corporation Call Center (US)

Louisville, KY United States

Incyte Corporation Call Center (US)

Durham, NC United States

Incyte Corporation Call Center (US)

Huntersville, NC United States

Incyte Corporation Call Center (US)

Winston-Salem, NC United States

Incyte Corporation Call Center (US)

Dallas, TX United States

Incyte Corporation Call Center (US)

Houston, TX United States

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.